What does TaiRx, Inc. do?

TaiRx, Inc. (6580.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6580.TWO's market cap?

TaiRx, Inc. (6580.TWO) has a market capitalization of approximately $1.38 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6580.TWO pay a dividend?

No — TaiRx, Inc. (6580.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6580.TWO profitable?

TaiRx, Inc. (6580.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6580.TWO

TaiRx, Inc.

TWO·Biotechnology · Healthcare

NT$12.30NT$0.20−1.60%

Market capNT$1.38B·Aug 26 6:07 AM UTC

Price Chart

NT$12.30−NT$0.20 (−1.60%)today

−56.13%CAGR −15.20%

Select date range

FromTo

Jun 21, 2017Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

6580.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$29.44M

Net Income−NT$233.31M

Net Margin−792.4%

Operating Cash Flow−NT$152.71M

Capital ExpendituresNT$84.00K

Free Cash Flow−NT$152.79M

Return on Equity−63.7%

Return on Invested Capital−23.7%

Net CashNT$274.73M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6580.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6580.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6580.TWO and 80,000+ other tickers.

About TaiRx, Inc.

TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed…

CEO: Du-Shieng Chien
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 29
Website: www.trx.com.tw

Peers

Peers Tab

7729.TWO

Steminent Biotherapeutics Inc.

Cap

NT$5.8B

6704.TWO

Gwo Xi Stem Cell Applied Technology Co. , Ltd

Cap

NT$1.8B

6864.TWO

Anti-Microbial Savior BioteQ Co., Ltd

Cap

NT$1.5B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6580.TWO

What does TaiRx, Inc. do?: TaiRx, Inc. (6580.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6580.TWO's market cap?: TaiRx, Inc. (6580.TWO) has a market capitalization of approximately $1.38 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6580.TWO pay a dividend?: No — TaiRx, Inc. (6580.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6580.TWO profitable?: TaiRx, Inc. (6580.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.